Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study

Tapinarof cream is a novel topical nonsteroidal agent that represents a unique class of anti‐inflammatory molecules targeting the aryl hydrocarbon receptor. Study 201851 was an open‐label, 2‐cohort sequential study that assessed the systemic pharmacokinetics, safety, and efficacy of tapinarof in adu...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology in drug development 2018-06, Vol.7 (5), p.524-531
Main Authors: Bissonnette, Robert, Vasist, Lakshmi S., Bullman, Jonathan N., Collingwood, Therese, Chen, Geng, Maeda‐Chubachi, Tomoko
Format: Article
Language:English
Subjects:
AhR agonist
atopic dermatitis
Eczema
Pharmacokinetics
Pharmacology
R&D
Research & development
systemic exposure
topical medicine
Transdermal medication
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tapinarof cream is a novel topical nonsteroidal agent that represents a unique class of anti‐inflammatory molecules targeting the aryl hydrocarbon receptor. Study 201851 was an open‐label, 2‐cohort sequential study that assessed the systemic pharmacokinetics, safety, and efficacy of tapinarof in adults with moderate to severe atopic dermatitis. A total of 11 participants were enrolled: 5 received 2% cream, and 6 received 1% cream. Tapinarof was systemically absorbed, and measurable amounts were detected in both cohorts. Generally, plasma exposure was greater with the 2% cream and decreased from day 1 to day 21. Median Tmax ranged from 1 to 4 hours. Preliminary efficacy results were similar between the 1% and 2% concentrations, with the 1% cream showing better tolerability based on 3 subjects in the 2% cohort who discontinued treatment because of systemic AEs. The efficacy and safety of 1% tapinarof support results of previous positive studies that used a different formulation. However, conclusions in the present study are limited because of the open‐label design and small number of participants. The 1% cream was selected as the concentration for use in future studies because of its lower AE incidence and efficacy comparable to the 2% cream.
ISSN:2160-763X
2160-7648
DOI:10.1002/cpdd.439